DengiAll Vaccine: Lessons from Brazil's Dengue Vaccine Safety Concerns

Context:

Brazil recently suspended the use of its dengue vaccine, Butantan-DV, after reports of serious adverse events, including two deaths and one intensive care admission among vaccine recipients. The development has drawn attention in India because DengiAll, India's indigenous dengue vaccine being developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR), is based on a similar technology platform.

What is DengiAll?

DengiAll is a tetravalent live-attenuated dengue vaccine, meaning it contains weakened forms of all four dengue virus serotypes:

• • • DENV-1
    • DENV-2
    • DENV-3
    • DENV-4

The vaccine aims to provide protection against all circulating dengue virus strains prevalent in India.

Key Challenge:

A major concern in dengue vaccination is a phenomenon called Antibody-Dependent Enhancement (ADE).

In dengue infection:

• • • Type-specific antibodies provide strong protection against a particular serotype.
    • Cross-reactive antibodies can recognize multiple serotypes.

However, when cross-reactive antibody levels decline, they may facilitate viral entry into immune cells rather than neutralize the virus. This can result in severe dengue infection, a process known as ADE.

ADE is considered one of the most significant safety challenges in dengue vaccine development.

India's Preparedness:

India's Phase-III DengiAll trial enrolled over 10,000 volunteers and participants are being monitored for two years after vaccination.

Experts have recommended:

• • • Detailed analysis of antibody responses against all four serotypes.
    • Careful assessment of ADE risk before regulatory approval.
    • A strong post-marketing pharmacovigilance system.
    • Long-term monitoring of vaccine recipients for adverse events.

About Dengue:

Dengue is a mosquito-borne viral disease caused by the Dengue Virus (DENV) and transmitted mainly by the Aedes aegypti mosquito.

Causative Agent: Dengue virus, an RNA virus belonging to the Flaviviridae family.

Four Serotypes: The virus exists in four distinct serotypes:

• • • DENV-1
    • DENV-2
    • DENV-3
    • DENV-4

Vector: Primarily spread by the Aedes aegypti mosquito, a daytime-biting mosquito.

Conclusion:

Brazil’s experience highlights that a dengue vaccine must not only be effective but also safe in the long term. India’s DengiAll vaccine has the potential to be a significant milestone in dengue control; however, ensuring its safety requires thorough evaluation of risks such as Antibody-Dependent Enhancement (ADE) and continuous monitoring over time.

 Frequently Asked Question (FAQs):

Q1. What is DengiAll?
Ans. DengiAll is India's indigenous tetravalent live-attenuated dengue vaccine being developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR). It contains weakened forms of all four dengue virus serotypes—DENV-1, DENV-2, DENV-3, and DENV-4.

Q2. What is Antibody-Dependent Enhancement (ADE)?
Ans. ADE is a phenomenon in which certain antibodies fail to neutralize the dengue virus and instead facilitate its entry into immune cells, potentially leading to severe dengue infection. It is considered one of the most important safety concerns in dengue vaccine development.

What causes dengue and how is it transmitted?
Ans. Dengue is caused by the Dengue Virus (DENV), an RNA virus belonging to the Flaviviridae family. It is transmitted primarily through the bite of an infected Aedes aegypti mosquito, which is a daytime-biting mosquito.